News & Events about Surface Oncology Inc.
Surface Oncology initiates clinical trial with antibody discovered using Vaccinexs ActivMAb Antibody Discovery PlatformROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and ...
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
Data further support SRF388 and SRF114 clinical development programsCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the ...
Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? PR Newswire NEW YORK, July 7, 2022 NEW YORK, July 7, 2022...
Globe Newswire
7 months ago
- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology(Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the ...